Incyte Corporation (INCY)vsRevolution Medicines Inc (RVMD)
INCY
Incyte Corporation
$102.38
+1.13%
HEALTHCARE · Cap: $21.68B
RVMD
Revolution Medicines Inc
$155.69
+4.02%
HEALTHCARE · Cap: $32.71B
Smart Verdict
WallStSmart Research — data-driven comparison
Incyte Corporation generates 722409% more annual revenue ($5.36B vs $742,000). INCY leads profitability with a 26.7% profit margin vs 0.0%. INCY earns a higher WallStSmart Score of 80/100 (A-).
INCY
Exceptional Buy80
out of 100
Grade: A-
RVMD
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+83.4%
Fair Value
$593.92
Current Price
$102.38
$491.54 discount
Intrinsic value data unavailable for RVMD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Earnings expanding 83.8% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Every $100 of equity generates 26 in profit
Keeps 27 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Areas to Watch
No major concerns identified
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : INCY
The strongest argument for INCY centers on PEG Ratio, EPS Growth, Debt/Equity. Profitability is solid with margins at 26.7% and operating margin at 25.6%. Revenue growth of 20.9% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : INCY
No major red flags identified for INCY, but monitor valuation.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
INCY profiles as a growth stock while RVMD is a value play — different risk/reward profiles.
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
INCY is growing revenue faster at 20.9% — sustainability is the question.
INCY generates stronger free cash flow (359M), providing more financial flexibility.
Bottom Line
INCY scores higher overall (80/100 vs 24/100), backed by strong 26.7% margins and 20.9% revenue growth. Both earn "Exceptional Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Incyte Corporation
HEALTHCARE · BIOTECHNOLOGY · USA
Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?